Taxes |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Income Tax Disclosure [Abstract] | |
| Taxes | 17. Taxes The Company’s U.S. provision for income tax benefit (expense) for the three and six months ended June 30, 2026 and 2025 reflects the tax effects of the Company's pre-tax results in each respective period. The Company’s wholly-owned Swiss subsidiary, Organogenesis GmbH, is subject to taxation in Switzerland and has a transfer pricing arrangement in place with Organogenesis Inc., its U.S. parent. The income tax rate for the six months ended June 30, 2026 was (25)%, a decrease from the U.S. statutory rate of 21% primarily due to the establishment of a full valuation allowance against its deferred tax assets. The income tax benefit (expense) for the three months ended June 30, 2026 and 2025 was $(45,387) and $2,442, respectively. The income tax benefit (expense) for the six months ended June 30, 2026 and 2025 was $(30,070) and $9,382, respectively. The increase in tax expense during the three and six months ended June 30, 2026 was a result of establishing a valuation allowance against the Company’s deferred tax assets. The Company will continue to assess the realizability of its deferred tax assets at each reporting date and will adjust the valuation allowance when sufficient positive evidence supports a change in its conclusion. The income tax benefit for the three and six months ended June 30, 2025, was primarily due to the generation of research and development tax credits. During the three months ended June 30, 2026, the Company updated its operating forecasts, which reflected expected taxable losses in the foreseeable future. As a result, the Company reassessed the realizability of its deferred tax assets. In making this assessment, the Company considered all available positive and negative evidence, including its cumulative loss position, historical operating results, forecasts of future taxable income, the reversal of existing taxable temporary differences and available tax-planning strategies. Based on the weight of the available evidence, the Company concluded that it is more likely than not that its deferred tax assets will not be realized and recorded a full valuation allowance against its net deferred tax assets as of June 30, 2026 |